Comprehensive Guide to Jaundice: Physiology, Types, Diagnosis, and Management

Introduction

Jaundice is the yellow discoloration of skin, sclera, mucous membranes and interstitial fluids caused by elevated serum bilirubin. Visible jaundice usually appears when bilirubin exceeds ~2.5 mg/dL.

Key Definitions

• Bilirubin: toxic breakdown product of hemoglobin, produced at 2–3 g/day.
• Hyperbilirubinemia: serum bilirubin >0.2–1.2 mg/dL; can be unconjugated (indirect) or conjugated (direct).
• Jaundice: clinically observable yellow hue when bilirubin reaches a visible level.
• Hemolysis: destruction of red blood cells releasing heme → bilirubin.
• Cholestasis: impaired bile flow leading to accumulation of conjugated bilirubin and bile acids.

Bilirubin Metabolism

1. Production – Hemoglobin → heme → biliverdin → unconjugated bilirubin (UB); UB binds albumin and travels to liver.
2. Uptake & Conjugation – Hepatocytes take up UB via specific receptors; UDP‑glucuronosyltransferase (UGT1A1) adds glucuronic acid, forming water‑soluble conjugated bilirubin (CB).
3. Excretion – CB is secreted into bile, stored in gallbladder, released into intestine; gut bacteria convert CB to urobilinogen, some re‑absorbed, some oxidized to stercobilin (fecal pigment) and a small amount excreted as urobilin in urine.

Types of Jaundice

Clinical Syndromes of Unconjugated Hyperbilirubinemia

• Gilbert Syndrome – Mild UGT1A1 deficiency; asymptomatic, occasional jaundice with stress or fasting.
• Crigler‑Najjar Type II – Moderate UGT1A1 deficiency; phenobarbital may induce enzyme activity.
• Crigler‑Najjar Type I – Near‑absent UGT1A1; severe neonatal jaundice, high risk of kernicterus, often fatal without transplant.

Clinical Syndromes of Conjugated Hyperbilirubinemia

• Dubin‑Johnson – Defective canalicular transport of CB; liver appears black.
• Rotor Syndrome – Similar transport defect without liver discoloration.
• Primary Biliary Cholangitis – Autoimmune, female predominance, anti‑mitochondrial antibodies, progressive intra‑hepatic cholestasis.
• Primary Sclerosing Cholangitis – Male predominance, associated with ulcerative colitis, fibrotic strictures of bile ducts.

Neonatal Jaundice

• Physiologic – Immature UGT1A1 + high fetal hemoglobin breakdown; peaks 3‑5 days, resolves 1‑2 weeks.
• Breast‑milk Jaundice – β‑glucuronidase in milk de‑conjugates bilirubin in gut, prolonging unconjugated hyperbilirubinemia.
• Kernicterus – Unconjugated bilirubin crosses immature BBB, causing irreversible neuronal damage.
• Management – Phototherapy (blue‑green light) converts UB to water‑soluble isomers; severe cases may need exchange transfusion or 10‑protoporphyrin to inhibit heme‑oxygenase.

Drugs Influencing Bilirubin

• Displacers (e.g., sulfonamides, high‑dose penicillins, rifampin) reduce albumin binding → more free UB.
• Enzyme Inhibitors – Certain antivirals impair UGT1A1, precipitating jaundice.

Hepatitis and Jaundice

• Infectious – Hepatitis A‑E, yellow fever, CMV, leptospirosis.
• Non‑infectious – Alcohol, carbon tetrachloride, toxic mushrooms, autoimmune hepatitis, Wilson’s disease, hemochromatosis, α‑1 antitrypsin deficiency.
• Hepatocyte injury reduces conjugation and bile secretion, producing mixed hyperbilirubinemia.

Cholestasis (Bile‑Flow Obstruction)

• Intra‑hepatic – Canalicular transporter defects (Dubin‑Johnson, Rotor), drug‑induced cholestasis, intra‑hepatic cholestasis of pregnancy.
• Extra‑hepatic – Gallstones, biliary strictures, pancreatic head tumors, choledochal cysts, liver flukes, Ascaris.
• Lab clues – Marked ALP & GGT rise, urine bilirubin positive, absent urobilinogen when CB cannot reach gut.

Diagnostic Approach

1. History – Onset, hemolysis signs, drug exposure, family history, alcohol/toxin use, pregnancy, prior surgeries.
2. Physical Exam – Distribution of jaundice, scleral involvement, hepatomegaly, splenomegaly, stigmata of chronic liver disease.
3. Laboratory Panel
4. Total & direct bilirubin.
5. CBC with reticulocyte count, haptoglobin, LDH, peripheral smear.
6. Liver enzymes (ALT, AST), ALP, GGT, 5′‑Nucleotidase.
7. PT/INR, albumin.
8. Urine bilirubin & urobilinogen.
9. Viral serologies, autoimmune markers, iron studies, ceruloplasmin.
10. Imaging – Abdominal ultrasound (first line), MRCP or ERCP for detailed biliary anatomy, PTC when ERCP not feasible.
11. Genetic Testing – When hereditary syndromes suspected (UGT1A1, ATP8B1, ABCB11, etc.).

Liver Enzyme Patterns

• Hemolysis – ↑ retic, macrocytosis, ↑ indirect bilirubin; normal AST/ALT, ALP, GGT; urine bilirubin absent.
• Hepatocellular injury – AST/ALT >10× ULN; ALT more liver‑specific; AST≈2×ALT suggests alcoholic injury.
• Cholestasis/Obstruction – Marked ALP, GGT, 5′‑N rise; modest AST/ALT; conjugated bilirubin in urine, pale stools, absent urobilinogen.
• Synthetic function – PT prolonged (distinguish vitamin K deficiency vs synthetic failure); albumin falls only in chronic severe disease.

Management Overview

• Treat underlying cause – Discontinue offending drugs, manage hemolysis, treat hepatitis, relieve obstruction (endoscopic stone removal, stenting, surgery).
• Supportive care – Hydration, nutrition, avoid fasting.
• Specific therapies
• Phototherapy for unconjugated jaundice (neonates, severe cases).
• Phenobarbital for Crigler‑Najjar type II.
• Ursodeoxycholic acid for cholestatic diseases.
• Liver transplantation for end‑stage disease or Crigler‑Najjar type I.

Practical Diagnostic Workflow

1. Initial labs (CBC, bilirubin fractions, AST, ALT, ALP, GGT, 5′‑N, PT/INR, albumin).
2. Urine dipstick for bilirubin and urobilinogen.
3. Ultrasound → assess ductal dilation.
4. MRCP/ERCP for detailed anatomy and therapeutic intervention.
5. Targeted serologies, autoimmune panels, tumor markers.
6. Consider liver biopsy or genetic testing if diagnosis remains unclear.

Illustrative Clinical Cases (Brief)

• Hemolytic anemia – High retic, indirect bilirubin, normal liver enzymes.
• Acute viral hepatitis – AST/ALT >10× ULN, mild ALP/GGT rise, conjugated bilirubin predominates.
• Alcoholic liver disease – AST≈2×ALT, modest ALP/GGT, little bilirubin elevation.
• Obstructive stone – Marked ALP/GGT, conjugated bilirubin in urine, pale stool, dilated CBD on US.
• Primary biliary cholangitis – High ALP/GGT, AMA positive, intra‑hepatic changes on MRCP.
• Pancreatic head carcinoma – Weight loss, obstructive labs, mass on imaging.

Key Points for Clinicians

• Enzyme magnitude matters: >10× normal points to acute hepatocellular necrosis.
• AST/ALT ratio >2 suggests alcoholic injury.
• Isolated ALP rise without GGT indicates bone/placental source.
• PT that corrects with vitamin K indicates deficiency; persistent prolongation signals synthetic failure.
• Urine analysis quickly differentiates obstructive from non‑obstructive jaundice.
• Follow imaging hierarchy: ultrasound → MRCP/ERCP → PTC → biopsy when needed.

Jaundice is a visible marker of disrupted bilirubin handling; accurate classification into pre‑hepatic, hepatic or post‑hepatic types and a systematic work‑up of labs and imaging enable clinicians to treat the underlying disease rather than merely the yellow discoloration.